Squarepoint Ops LLC Buys Shares of 255,907 Arrowhead Pharmaceuticals, Inc. $ARWR

Squarepoint Ops LLC bought a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 255,907 shares of the biotechnology company's stock, valued at approximately $20,859,000. Squarepoint Ops LLC owned about 0.18% of Arrowhead Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently modified their holdings of ARWR. Versant Capital Management Inc boosted its holdings in shares of Arrowhead Pharmaceuticals by 285.1% during the 2nd quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company's stock valued at $27,000 after acquiring an additional 248 shares in the last quarter. Carolina Wealth Advisors LLC increased its holdings in Arrowhead Pharmaceuticals by 80.6% in the 2nd quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company's stock worth $28,000 after purchasing an additional 154 shares in the last quarter. Tsfg LLC bought a new position in Arrowhead Pharmaceuticals in the fourth quarter valued at about $25,000. Optiver Holding B.V. raised its position in Arrowhead Pharmaceuticals by 83.8% in the first quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company's stock valued at $26,000 after purchasing an additional 186 shares during the last quarter. Finally, Persistent Asset Partners Ltd acquired a new stake in shares of Arrowhead Pharmaceuticals during the second quarter valued at about $39,000. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. Chardan Capital restated a "buy" rating and set a $115.00 price target on shares of Arrowhead Pharmaceuticals in a report on Monday, August 31st. Piper Sandler reiterated an "overweight" rating and set a $126.00 target price (up from $110.00) on shares of Arrowhead Pharmaceuticals in a research report on Thursday, July 23rd. B. Riley Financial boosted their target price on shares of Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the stock a "buy" rating in a report on Thursday, July 30th. Wall Street Zen raised shares of Arrowhead Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, June 27th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Arrowhead Pharmaceuticals in a report on Monday, August 17th. Ten investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $99.15.

Arrowhead Pharmaceuticals Price Performance

ARWR stock opened at $85.11 on Wednesday. The firm has a market cap of $11.99 billion, a price-to-earnings ratio of -37.83 and a beta of 1.28. The company has a quick ratio of 5.90, a current ratio of 5.90 and a debt-to-equity ratio of 1.77. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $27.15 and a 12-month high of $95.49. The company's fifty day simple moving average is $84.30 and its 200 day simple moving average is $74.69.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.13). Arrowhead Pharmaceuticals had a negative return on equity of 60.06% and a negative net margin of 47.79%.The business had revenue of $75.25 million during the quarter, compared to the consensus estimate of $44.17 million. During the same period last year, the business posted ($1.26) earnings per share. The business's revenue was up 171.0% on a year-over-year basis. On average, analysts expect that Arrowhead Pharmaceuticals, Inc. will post -3.62 earnings per share for the current year.

Insider Activity at Arrowhead Pharmaceuticals

In other news, Director Michael Perry sold 11,600 shares of Arrowhead Pharmaceuticals stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $87.30, for a total value of $1,012,680.00. Following the completion of the sale, the director owned 111,459 shares in the company, valued at $9,730,370.70. The trade was a 9.43% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Adeoye Olukotun sold 2,000 shares of the firm's stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $86.96, for a total transaction of $173,920.00. Following the completion of the sale, the director owned 31,600 shares of the company's stock, valued at $2,747,936. The trade was a 5.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 3.60% of the company's stock.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company's approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company's pipeline includes multiple candidates in various stages of development.

Want to see what other hedge funds are holding ARWR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.